Skip to main content
. 2024 Jan 28;13(1):173–190. doi: 10.1007/s40119-023-00345-2

Table 2.

Change in echo variables from baseline to weeks 26 and 52 (Echo subgroup, N = 45)

Echo variables n Baseline Mean (SD) Change from baseline to week 26 LS meana (95% CL) n Change from baseline to week 52 LS meana (95% CL)
RV fractional area change, % 42 25.9 (11.9) 7.5 (4.4, 10.7) 38 7.1 (4.3, 9.9)
TAPSE, mm 39 16.4 (3.5) 2.5 (1.4, 3.6) 35 3.2 (2.2, 4.2)
2D global longitudinal RV strain, % 36 − 13.9 (5.7) − 3.0 (− 4.7, − 1.4) 33 − 3.5 (− 4.9, − 2.1)
RV stroke volumeb, mL 28 68.4 (22.6) 11.6 (3.2, 20.0) 25 15.5 (4.6, 26.5)
RV stroke volume index, mL/m2 28 39.1 (12.8) 5.9 (1.7, 10.1) 25 8.7 (2.2, 15.2)
RV cardiac index, L/min/m2 28 2.9 (1.0) 0.23 (− 0.10, 0.57) 25 0.46 (− 0.03, 0.94)
RV cardiac output, L/min 28 5.1 (1.9) 0.47 (− 0.12, 1.06) 25 0.81 (0.02, 1.60)
LV stroke volumec, mL 29 51.5 (18.2) 9.6 (3.8, 15.5) 25 11.9 (5.1, 18.6)
RV myocardial performance indexc 29 0.69 (0.38) − 0.20 (− 0.26, − 0.15) 25 − 0.30 (− 0.40, − 0.20)
Mitral E/A ratio 35 0.95 (0.35) 0.19 (0.06, 0.32) 31 0.30 (0.16, 0.44)
RV end-diastolic diameter, mm 43 45.3 (7.1) − 2.8 (− 4.7, − 0.8) 38 − 3.2 (− 5.1, − 1.4)
LV end-diastolic volume, mL 32 70.6 (27.6) 15.1 (8.8, 21.4) 31 16.5 (8.9, 24.2)
Tricuspid regurgitation PJV, m/s 21 4.3 (0.74) − 0.36 (− 0.70, − 0.03) 19 − 0.29 (− 0.63, 0.05)
Heart rate, bpm 43 78.3 (14.6) − 7.0 (− 10.2, − 3.8) 38 − 8.2 (− 12.0, − 4.4)

aAnalyzed using ANCOVA with a factor for PAH background therapy and a covariate for baseline parameter value

bDetermined from pulmonic valve Doppler and pulmonary artery annulus dimension

cBy pulsed-wave Doppler

ANCOVA analysis of covariance, bpm beats per minute, CL confidence limit, echo echocardiography, LS least squares, LV left ventricular, PAH pulmonary arterial hypertension, PJV peak jet velocity, RV right ventricular, SD standard deviation, TAPSE tricuspid annular plane systolic excursion